Free Trial
NASDAQ:GLSI

Greenwich LifeSciences (GLSI) Stock Price, News & Analysis

Greenwich LifeSciences logo
$12.08 +0.30 (+2.55%)
Closing price 08/14/2025 04:00 PM Eastern
Extended Trading
$12.12 +0.04 (+0.29%)
As of 04:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Greenwich LifeSciences Stock (NASDAQ:GLSI)

Key Stats

Today's Range
$11.70
$12.70
50-Day Range
$8.76
$12.49
52-Week Range
$8.06
$16.50
Volume
99,641 shs
Average Volume
67,336 shs
Market Capitalization
$161.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$39.00
Consensus Rating
Buy

Company Overview

Greenwich LifeSciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

GLSI MarketRank™: 

Greenwich LifeSciences scored higher than 29% of companies evaluated by MarketBeat, and ranked 821st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Greenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Greenwich LifeSciences has received no research coverage in the past 90 days.

  • Read more about Greenwich LifeSciences' stock forecast and price target.
  • Earnings Growth

    Earnings for Greenwich LifeSciences are expected to decrease in the coming year, from ($0.80) to ($0.81) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Greenwich LifeSciences is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Greenwich LifeSciences is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Greenwich LifeSciences has a P/B Ratio of 63.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    17.36% of the float of Greenwich LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Greenwich LifeSciences has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Greenwich LifeSciences has recently increased by 4.00%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Greenwich LifeSciences does not currently pay a dividend.

  • Dividend Growth

    Greenwich LifeSciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    17.36% of the float of Greenwich LifeSciences has been sold short.
  • Short Interest Ratio / Days to Cover

    Greenwich LifeSciences has a short interest ratio ("days to cover") of 20, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Greenwich LifeSciences has recently increased by 4.00%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Greenwich LifeSciences has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Greenwich LifeSciences this week, compared to 1 article on an average week.
  • Search Interest

    Only 2 people have searched for GLSI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Greenwich LifeSciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    51.67% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 4.16% of the stock of Greenwich LifeSciences is held by institutions.

  • Read more about Greenwich LifeSciences' insider trading history.
Receive GLSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter.

GLSI Stock News Headlines

HIDDEN IN THE BOOK OF GENESIS…
“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 trillion vault of untapped American wealth. Former CIA advisor Jim Rickards calls it the “Old Testament Wealth Code” — and says it could transform your financial future. He’s revealing everything in a new presentation.
See More Headlines

GLSI Stock Analysis - Frequently Asked Questions

Greenwich LifeSciences' stock was trading at $11.23 at the start of the year. Since then, GLSI stock has increased by 7.6% and is now trading at $12.08.

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by $0.06.

Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital served as the underwriter for the IPO.

Greenwich LifeSciences' top institutional investors include Geode Capital Management LLC (1.04%), Marshall Wace LLP (0.42%) and Police & Firemen s Retirement System of New Jersey (0.02%). Insiders that own company stock include Snehal Patel and Jaye Thompson.
View institutional ownership trends
.

Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Meta Platforms (META) and NVIDIA (NVDA).

Company Calendar

Last Earnings
5/20/2025
Today
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:GLSI
CIK
1799788
Fax
N/A
Employees
3
Year Founded
N/A

Price Target and Rating

High Price Target
$39.00
Low Price Target
$39.00
Potential Upside/Downside
+222.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.26)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$15.79 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-450.87%
Return on Assets
-333.18%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.91
Quick Ratio
1.91

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.19 per share
Price / Book
63.58

Miscellaneous

Outstanding Shares
13,370,000
Free Float
6,461,000
Market Cap
$161.51 million
Optionable
Not Optionable
Beta
1.65

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:GLSI) was last updated on 8/15/2025 by MarketBeat.com Staff
From Our Partners